Description

IVERHUMAN 3 MG

Indications

IVERHUMAN 3 MG is primarily indicated for the treatment of various parasitic infections, particularly those caused by helminths and certain ectoparasites. It is commonly used to manage conditions such as strongyloidiasis, ascariasis, and other infections caused by nematodes. Additionally, IVERHUMAN may be utilized in the treatment of scabies and lice infestations, providing a broad-spectrum approach to parasitic diseases.

Mechanism of Action

The active ingredient in IVERHUMAN, ivermectin, exerts its antiparasitic effects through a unique mechanism of action. Ivermectin binds to specific chloride channels, which are dependent on gamma-aminobutyric acid (GABA), leading to an increase in the permeability of the cell membrane to chloride ions. This hyperpolarizes the nerve and muscle cells of the parasites, resulting in paralysis and eventual death of the organism. Additionally, ivermectin disrupts the function of certain neurotransmitters, further contributing to the elimination of the parasites.

Pharmacological Properties

IVERHUMAN is characterized by its high lipophilicity, which enhances its absorption and distribution within the body. After oral administration, ivermectin is rapidly absorbed, with peak plasma concentrations typically occurring within 4 to 5 hours. The drug is extensively distributed in body tissues, including the liver, lungs, and muscles. It is metabolized primarily by the liver through the cytochrome P450 system and has a half-life ranging from 12 to 36 hours, depending on the individual’s metabolic rate. The drug is excreted mainly in the feces, with minimal amounts found in urine.

Contraindications

IVERHUMAN should not be used in individuals with known hypersensitivity to ivermectin or any of the excipients in the formulation. It is also contraindicated in patients with severe liver impairment, as this may lead to increased plasma concentrations and a higher risk of adverse effects. Caution is advised when considering the use of IVERHUMAN in patients with a history of neurological disorders or those who are pregnant or breastfeeding, as the safety profile in these populations has not been fully established.

Side Effects

While IVERHUMAN is generally well tolerated, some patients may experience side effects. Common adverse reactions include dizziness, nausea, diarrhea, and abdominal pain. In rare cases, more severe reactions such as hypotension, allergic reactions, or neurological symptoms may occur. Patients should be advised to report any unusual symptoms or severe side effects to their healthcare provider promptly. Monitoring for potential adverse effects is crucial, especially in patients with underlying health conditions.

Dosage and Administration

The recommended dosage of IVERHUMAN varies depending on the specific indication and the patient’s weight. For the treatment of strongyloidiasis, the typical adult dose is 200 micrograms per kilogram of body weight, administered as a single oral dose. For other parasitic infections, the dosage may differ, and it is essential to follow the prescribing physician’s recommendations. IVERHUMAN should be taken on an empty stomach, preferably with water, to enhance absorption. It is important for patients to adhere to the prescribed regimen to ensure optimal therapeutic outcomes.

Interactions

IVERHUMAN may interact with certain medications, which can affect its efficacy and safety. Concomitant use of ivermectin with other drugs that are metabolized by the cytochrome P450 system may alter plasma concentrations of either agent. Notably, caution should be exercised when using IVERHUMAN alongside medications such as benzodiazepines, barbiturates, or other central nervous system depressants, as this may potentiate sedative effects. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Before initiating treatment with IVERHUMAN, a thorough medical history and assessment should be conducted. Special precautions should be taken in patients with compromised liver function, as they may be at increased risk for adverse effects. Additionally, patients with a history of seizures or other neurological disorders should be monitored closely during treatment. It is also essential to consider the potential for drug interactions, particularly in patients taking multiple medications. Pregnant and breastfeeding women should consult their healthcare provider to weigh the risks and benefits of treatment with IVERHUMAN.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of IVERHUMAN in the treatment of parasitic infections. A randomized controlled trial demonstrated that ivermectin was effective in reducing the burden of strongyloidiasis, with a significant percentage of patients achieving parasitological cure. Other studies have shown that ivermectin is effective against various ectoparasites, including lice and scabies, with high cure rates and minimal side effects. These findings support the use of IVERHUMAN as a valuable therapeutic option for managing parasitic infections.

Conclusion

IVERHUMAN 3 MG is a potent antiparasitic medication indicated for the treatment of a range of parasitic infections. Its unique mechanism of action, pharmacological properties, and clinical efficacy make it a valuable tool in the management of these conditions. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective use. Patients should be educated about the importance of adherence to the prescribed regimen and the need for monitoring during treatment.